Japan Asia is emerging as a critical frontier in oncology research, yet much of global drug development continues to overlook the region’s specific clinical needs. At the National Cancer Center Japan, Kenichi Nakamura is working to change that dynamic through ATLAS, a pan-Asian clinical trial network designed to enable more coordinated,…
Hong Kong Sabrina Chan, Senior Executive at HKAPI, highlights progress in Hong Kong’s biomedical ambitions, including establishing an independent regulator, expanding clinical trial capacity via the Greater Bay Area Clinical Trial Institute (GBAICTI), and leveraging 34 years of real-world health data. She underscores efforts to enhance primary healthcare, support rare disease access,…
France Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de Lyon (HCL) network, the region hosts 12 percent of all hospital beds in France and makes a core contribution to…
France Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s most investable life sciences hubs. While less well-known internationally than Basel, Barcelona, London, or Paris, Lyon stands out from the…
Taiwan Taiwan’s clinical research ecosystem has evolved rapidly in recent years, reflecting Asia’s growing role in global drug development. Samuel Su, Founder and CEO of Bestat Pharmaservices, discusses how the organisation has expanded from a data-driven CRO into an integrated development partner supporting preclinical research, multi-regional clinical trials, and international regulatory…
Taiwan Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho, Superintendent and Professor of Neurosurgery, explains how the institution operates as an integrated innovation platform, advancing cell and gene therapies,…
MEA For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward to 2026, and massive genome projects across the Gulf region are attempting to shift the narrative. Backed by immense sovereign…
France France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for complex, high-science clinical research. In oncology and rare diseases clinical R&D especially, France punches well above its weight, supported by…
MEA CTI EMEA Managing Director Alaa Assem is a physician, ophthalmologist and MBA holder with over 30 years of experience in pharma and clinical research organisations. Since joining CTI, he has strengthened the company’s presence in the Middle East, focusing on rare disease, gene and cell therapy, oncology, and transplantation. CTI…
MEA As healthcare systems across the GCC accelerate their focus on innovation, access, and advanced therapies, Novartis is positioning the region at the centre of its long-term strategy. Mohamed Ezz Eldin shares how global priorities are translated into local execution, from rare disease care and genomics to clinical research and innovative…
MEA Biogen’s transformation into a rare disease-focused organisation is reshaping how innovation reaches patients in the GCC. Diederik Kok, the company’s GCC Head reflects on how global strategy translates into regional execution, from launching first-in-class therapies and navigating access for ultra-rare conditions, to building sustainable financing models, clinical research capacity, and…
Hong Kong Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute (GBAICTI), Hong Kong’s long-established academic and regulatory strengths are being connected with the scale, infrastructure, and talent of the wider…
See our Cookie Privacy Policy Here
